dexfenfluramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anorexics | 832 | 3239-44-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.85 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 89 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 11 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 11 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.66 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 14 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 26.77 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1970 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A08AA04 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
| CHEBI has role | CHEBI:35941 | serotonin agonists |
| CHEBI has role | CHEBI:50949 | SSRI |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Obesity | indication | 414916001 | DOID:9970 |
| Alcoholism | contraindication | 7200002 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.22 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | Ki | 6.00 | PDSP | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.28 | PDSP | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.66 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 6.18 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.08 | PDSP | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.61 | PDSP | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.38 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.79 | PDSP | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.04 | PDSP | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 5.26 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 6.57 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.62 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.73 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.58 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.33 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.16 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.72 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 5.90 | PDSP | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.71 | PDSP | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.85 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.47 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024029 | VUID |
| N0000022034 | NUI |
| D03713 | KEGG_DRUG |
| 155142 | RXNORM |
| 4020972 | VANDF |
| 4024029 | VANDF |
| C0011786 | UMLSCUI |
| CHEBI:439329 | CHEBI |
| CHEMBL248702 | ChEMBL_ID |
| DB01191 | DRUGBANK_ID |
| D020372 | MESH_DESCRIPTOR_UI |
| 66265 | PUBCHEM_CID |
| 5818 | INN_ID |
| 3239-45-0 | SECONDARY_CAS_RN |
| E35R3G56OV | UNII |
| DB00574 | DRUGBANK_ID |
| 4557 | MMSL |
| d04006 | MMSL |
| 004127 | NDDF |
| 004128 | NDDF |
| 322047008 | SNOMEDCT_US |
| 412366002 | SNOMEDCT_US |
| CHEMBL1887891 | ChEMBL_ID |
Pharmaceutical products:
None